文献速递胰腺与胆道疾病

胰腺靶向AAV8-hSPINK1基因治疗可安全有效地预防小鼠胰腺炎

Pancreas-directed AAV8-hSPINK1 gene therapy safely and effectively protects against pancreatitis in mice.
PubMed 文献 · Gut · 2024-06-06

本研究构建了靶向胰腺的AAV8-hSPINK1表达载体,通过腹腔注射小鼠,在三种胰腺炎模型中验证其安全性和有效性。结果显示载体特异性靶向胰腺、转导效率高,单次给药可减轻胰腺炎严重程度、减少纤维化进展、降低凋亡和自噬水平并加速恢复。

要点

  • AAV8-hSPINK1载体特异性靶向胰腺,最佳表达剂量为2×10^11 vg/只。
  • 注射后4周hSPINK1表达和疗效达峰值,至少维持8周显著水平。
  • 三种小鼠模型中单次给药均减轻胰腺炎严重程度并加速恢复。

核心结论

  • 单次注射AAV8-hSPINK1可安全靶向胰腺,转导效率高,并有效改善小鼠胰腺炎表型。
  • 该方法有望用于慢性胰腺炎的预防和治疗。

研究设计与样本

  • 临床前研究,构建衣壳优化的AAV8介导的hSPINK1表达载体(AAV8-hSPINK1)。
  • 小鼠通过腹腔注射接受AAV8-hSPINK1治疗。
  • 在三种小鼠模型(雨蛙素诱导胰腺炎、胰管结扎和Spink1 c.194+2T>C小鼠模型)中研究其预防和治疗效果。

主要发现

  • AAV8-hSPINK1载体特异性且安全地靶向胰腺,对心、肺、脾、肝和肾的器官趋向性低,转导效率高,最佳表达剂量为2×10^11 vg/只。
  • hSPINK1的表达和疗效在注射后4周达峰值,并至少维持8周显著水平。
  • 在全部三种小鼠模型中,疾病发作前单次给予AAV8-hSPINK1显著减轻胰腺炎严重程度,减少纤维化进展,降低胰腺凋亡和自噬水平,并加速胰腺炎恢复过程。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Currently, there is no cure for chronic pancreatitis (CP). Germline loss-of-function variants in SPINK1 (encoding trypsin inhibitor) are common in patients with CP and are associated with acute attacks and progression of the disease. This preclinical study was conducted to explore the potential of adeno-associated virus type 8 (AAV8)-mediated overexpression of human SPINK1 (hSPINK1) for pancreatitis therapy in mice. DESIGN: A capsid-optimised AAV8-mediated hSPINK1 expression vector (AAV8-hSPINK1) to target the pancreas was constructed. Mice were treated with AAV8-hSPINK1 by intraperitoneal injection. Pancreatic transduction efficiency and safety of AAV8-hSPINK1 were dynamically evaluated in infected mice. The effectiveness of AAV8-hSPINK1 on pancreatitis prevention and treatment was studied in three mouse models (caerulein-induced pancreatitis, pancreatic duct ligation and Spink1 c.194+2T>C mouse models). RESULTS: The constructed AAV8-hSPINK1 vector specifically and safely targeted the pancreas, had low organ tropism for the heart, lungs, spleen, liver and kidneys and had a high transduction efficiency (the optimal expression dose was 2×1011 vg/animal). The expression and efficacy of hSPINK1 peaked at 4 weeks after injection and remained at significant level for up to at least 8 weeks. In all three mouse models, a single dose of AAV8-hSPINK1 before disease onset significantly alleviated the severity of pancreatitis, reduced the progression of fibrosis, decreased the levels of apoptosis and autophagy in the pancreas and accelerated the pancreatitis recovery process. CONCLUSION: One-time injection of AAV8-hSPINK1 safely targets the pancreas with high transduction efficiency and effectively ameliorates pancreatitis phenotypes in mice. This approach is promising for the prevention and treatment of CP.

来源:Gut,查看原文。版权归原作者所有。

引用

  1. Wang YC, Mao XT, Sun C, et al. Pancreas-directed AAV8-hSPINK1 gene therapy safely and effectively protects against pancreatitis in mice. Gut. 2024. PMID: 38553043. doi:10.1136/gutjnl-2023-330788

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。